Targeting Angiogenesis in Bladder Cancer

Area of Science:

• Oncology
• Medical Oncology
• Clinical Trials

Background:

• Urothelial carcinoma is a significant cause of cancer mortality.
• Platinum chemotherapy is a standard first-line treatment for advanced urothelial carcinoma.
• Limited effective treatment options exist for patients with platinum-refractory disease.

Purpose of the Study:

• To evaluate the efficacy and safety of ramucirumab plus docetaxel versus placebo plus docetaxel in patients with advanced or metastatic urothelial carcinoma.
• To determine the impact of ramucirumab on progression-free survival (PFS) in this patient population.

Main Methods:

• The phase III RANGE study was a randomized, double-blind, placebo-controlled trial.
• Patients received either ramucirumab plus docetaxel or placebo plus docetaxel.
• Progression-free survival was the primary endpoint.

Main Results:

• Adding ramucirumab to docetaxel demonstrated a statistically significant improvement in progression-free survival compared to placebo plus docetaxel.
• The safety profile of ramucirumab in combination with docetaxel was consistent with previous studies.

Conclusions:

• Ramucirumab plus docetaxel represents a potential new treatment option for patients with advanced or metastatic urothelial carcinoma refractory to platinum chemotherapy.
• These findings support the use of ramucirumab in this specific patient subgroup, potentially improving clinical outcomes.